- Retraction Note
- Open access
- Published:
Retraction Note: Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway
Cancer Cell International volume 24, Article number: 320 (2024)
Cancer Cell International (2020) 20:97
Retraction Note
The Editor-in-Chief has retracted this article at the authors’ request. After publication, concerns were raised regarding the data included in the figures. Specifically:
-
Fig. 1e 0 Gy images appear to be assembled incorrectly, and the EdU images for 0.125 and 0.25 µM S109 appear highly similar;
-
Fig. 2c 0.25 µM 6 Gy image appears highly similar to Fig. 1i (C6 cells, 25 µM GDC-0449) of another article [1] from the same author group;
-
Fig. 4b 0 mg/kg S109 10 Gy Day 10 (2nd mouse) and Day 18 (2nd mouse) images appear highly similar;
-
Fig. 4e 0 mg/kg S109 10 Gy and 50 mg/kg S109 0 Gy images appear to overlap.
The authors have stated that incorrect images were included in the figure panels during figure preparation. Although the authors believe that these issues do not affect the conclusions of the study, they requested to retract the article to prevent any potential confusion or misinterpretation by readers.
Xuejiao Liu stated on behalf of all authors that all authors agree to this retraction.
References
Tu Y, Niu M, Xie P, et al. Smoothened is a poor prognosis factor and a potential therapeutic target in glioma. Sci Rep. 2017;7:42630. https://doiorg.publicaciones.saludcastillayleon.es/10.1038/srep42630.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12935-020-01186-y.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Liu, X., Tu, Y., Wang, Y. et al. Retraction Note: Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway. Cancer Cell Int 24, 320 (2024). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12935-024-03508-w
Accepted:
Published:
DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12935-024-03508-w